Skip to content
value.today
Veru Inc. logo

Veru Inc.

VERU
$41 Mmarket cap on Oct 9, 2026-58.3% since Jan 2024
Compare
World rank
#21,918
Revenue
—
For year ending September-2025
Net income
$-23 M
SEC filing
Employees
—

Veru Inc. in brief

Veru Inc. is a listed company in the Biotechnology industry, based in Miami, Florida, USA. Its market value was $41 M on 9 October 2026, which makes it the 21,918th largest listed company in the world and the 3,937th largest in the USA on this site. Mitchell Shuster Steiner is its chief executive. Its shares trade under the symbol VERU (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Veru Inc.

Veru is a is an Oncology Biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The company annual revenue is 50 million USD and 386 employee as on 2020. The headquarters is in USA.

Veru Inc. timeline

3 events, 1996–2021
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2017
  4. ✎
    Renamed Veru Inc.
    Formerly Female Health Co.
  5. 2021
  6. 💰
    Record revenue of $61 million
    FY2021, the highest of the 7 years on record.

Events of Veru Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$162 M$323 M$485 M$647 M2020202120222023202420252026

World rank over time

▼ down 6,655 places since 2020
2020-01-01: #15354#15,35420202021-01-01: #10304#10,30420212022-01-07: #14203#14,20320222022-12-25: #13763#13,76320222023-07-30: #21147#21,14720232024-01-05: #21494#21,49420242026-03-08: #11236#11,23620262026-08-01: #19608#19,60820262026-10-09: #22009#22,0092026

Rank in USA: #3,149 (Jan 2020) · #2,610 (Jan 2021) · #3,054 (Jan 2022) · #2,820 (Dec 2022) · #4,137 (Jul 2023) · #3,696 (Jan 2024) · #2,189 (Mar 2026) · #3,753 (Aug 2026) · #3,913 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
2.3×
Free cash flow yield
-72.8%
Net margin
—
Operating margin
—
Return on equity
-124.0%
Liabilities / assets
38.5%
Payout ratio
262.5%
Revenue growth
+3.6%
R&D / revenue
75.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Sep 2018: revenue $16M, net income $-24M$16MFY18Fiscal year ending Sep 2019: revenue $32M, net income $-12M$32MFY19Fiscal year ending Sep 2020: revenue $43M, net income $-19M$43MFY20Fiscal year ending Sep 2021: revenue $61M, net income $7M$61MFY21Fiscal year ending Sep 2022: revenue $39M, net income $-84M$39MFY22Fiscal year ending Sep 2023: revenue $16M, net income $-93M$16MFY23Fiscal year ending Sep 2024: revenue $17M, net income $-38M$17MFY24Fiscal year ending Sep 2025: revenue —, net income $-23M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Sep 2025——$-25M$-23M—
Sep 2024$17M+3.6%$-36M$-38M-223.8%
Sep 2023$16M-58.6%$-94M$-93M-571.5%
Sep 2022$39M-35.8%$-83M$-84M-213.6%
Sep 2021$61M+43.8%$13M$7M12.1%
Sep 2020$43M+33.9%$-15M$-19M-44.5%
Sep 2019$32M+100.5%$-6M$-12M-37.8%
Sep 2018$16M—$-21M$-24M-150.9%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Sep 2025$-30M$0M$-30M——
Sep 2024$-22M$0M$-22M——
Sep 2023$-88M$1M$-89M$-1.10—
Sep 2022$-48M$1M$-48M$-1.05—
Sep 2021$-16M$0M$-16M$0.09—
Sep 2020$-2M$0M$-2M$-0.28—
Sep 2019$-5M$0M$-6M$-0.19—
Sep 2018$-12M$0M$-12M$-0.44—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024 (from the annual report): revenue $7M, net income $-9M$7MSep ’24Three months to Dec 2024: revenue —, net income $-9M—Dec ’24Three months to Mar 2025: revenue —, net income $-8M—Mar ’25Three months to Jun 2025: revenue —, net income $-7M—Jun ’25Three months to Sep 2025 (from the annual report): revenue —, net income $1M—Sep ’25Three months to Dec 2025: revenue —, net income $-5M—Dec ’25Three months to Mar 2026: revenue —, net income $-3M—Mar ’26Three months to Jun 2026: revenue —, net income $-7M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Veru Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-25 M
Net income
$-23 M

For year ending September-2025 · source: SEC filing

Balance sheet

Total assets
$30 M
Total liabilities
$12 M
Total equity
$18 M

As of September-2025

Top 56 institutional investors in Veru Inc.#

As of Sep 30, 2026
56 institutions held 2.6 M shares (about 15.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 11.6%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Veru Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC690,105-8,334 (-1.19%)4.05%$2 MNov 13, 2026
2Renaissance Technologies LLC207,450+43,000 (+26.15%)1.22%$1 MNov 12, 2026
3Oppenheimer & Co Inc196,547-14,296 (-6.78%)1.15%$1 MOct 26, 2026
4Geode Capital Management, LLC194,231+39,155 (+25.25%)1.14%$1 MNov 6, 2026
5BlackRock, Inc.164,802-2,282 (-1.37%)0.97%$0 MNov 13, 2026
6Summit Financial, LLC140,955-910 (-0.64%)0.83%$0 MNov 12, 2026
7Gsa Capital Partners LLP129,431-27,905 (-17.74%)0.76%$0 MNov 16, 2026
8Schonfeld Strategic Advisors LLC88,798New0.52%$0 MNov 16, 2026
9Raymond James Financial Inc81,872-3,097 (-3.64%)0.48%$0 MNov 12, 2026
10Vanguard Fiduciary Trust Co81,2300 (0.00%)0.48%$0 MNov 13, 2026
11Choreo, LLC74,8130 (0.00%)0.44%$0 MOct 28, 2026
12NewEdge Advisors, LLC60,719-9,720 (-13.80%)0.36%$0 MNov 13, 2026
13Blair William & Co/il60,000+2,000 (+3.45%)0.35%$0 MNov 10, 2026
14State Street Corp55,0040 (0.00%)0.32%$0 MNov 12, 2026
15Group One Trading LLC54,955New0.32%$0 MNov 10, 2026
16Two Sigma Investments, LP40,374New0.24%$0 MNov 16, 2026
17ADAR1 Capital Management, LLC35,0000 (0.00%)0.21%$0 MNov 16, 2026
18Jane Street Group, LLC34,177-93,676 (-73.27%)0.20%$0 MNov 12, 2026
19Northern Trust Corp29,809-46 (-0.15%)0.17%$0 MNov 16, 2026
20Price T Rowe Associates Inc /MD/24,7650 (0.00%)0.15%$0 MNov 16, 2026
21Quantinno Capital Management LP20,0000 (0.00%)0.12%$0 MNov 13, 2026
22Susquehanna International Group, LLP19,872+7,275 (+57.75%)0.12%$0 MNov 16, 2026
23XTX Topco Ltd19,196New0.11%$0 MNov 16, 2026
24Osaic Holdings, Inc.16,101-152 (-0.94%)0.09%$0 MNov 12, 2026
25Morgan Stanley12,634+5,972 (+89.64%)0.07%$0 MNov 13, 2026
Show all 56: investors 26 to 56
Institutional investors 26 to 56 in Veru Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Integrated Wealth Concepts LLC12,290+25 (+0.20%)0.07%$0 MNov 17, 2026
27Axq Capital, LP10,756New0.06%$0 MNov 12, 2026
28Northwestern Mutual Wealth Management Co10,0000 (0.00%)0.06%$0 MNov 13, 2026
29Prime Capital Investment Advisors, LLC10,0000 (0.00%)0.06%$0 MOct 20, 2026
30Allworth Financial LP7,8170 (0.00%)0.05%$0 MNov 17, 2026
31Vanguard Global Advisers, LLC5,8210 (0.00%)0.03%$0 MNov 13, 2026
32UBS Group AG3,612+3,530 (+4304.88%)0.02%$0 MNov 10, 2026
33Tower Research Capital LLC (TRC)1,842+100 (+5.74%)0.01%$0 MNov 16, 2026
34Jpmorgan Chase & Co1,249+876 (+234.85%)0.01%$0 MNov 12, 2026
35Chung Wu Investment Group, LLC1,0000 (0.00%)0.01%$0 MNov 3, 2026
36Strategic Investment Solutions, Inc. /IL9000 (0.00%)0.01%$0 MNov 12, 2026
37Wells Fargo & Company/mn750-6,235 (-89.26%)0.00%$0 MNov 16, 2026
38Quent Capital, LLC6880 (0.00%)0.00%$0 MNov 13, 2026
39Rossby Financial, LCC6000 (0.00%)0.00%$0 MNov 5, 2026
40SBI Securities Co., Ltd.418+3 (+0.72%)0.00%$0 MOct 22, 2026
41Signaturefd, LLC3000 (0.00%)0.00%$0 MOct 23, 2026
42Axiom Investment Management LLC2500 (0.00%)0.00%$0 MNov 3, 2026
43Caitong International Asset Management Co., Ltd228-1,128 (-83.19%)0.00%$0 MOct 29, 2026
44Harbour Investments, Inc.200-5 (-2.44%)0.00%$0 MNov 9, 2026
45Rockefeller Capital Management L.P.2000 (0.00%)0.00%$0 MNov 13, 2026
46PlanVest Financial, Inc1740 (0.00%)0.00%$0 MNov 9, 2026
47Farther Finance Advisors, LLC130New0.00%$0 MOct 8, 2026
48Trust Co Of Toledo NA /oh/1000 (0.00%)0.00%$0 MOct 16, 2026
49Lodestone Wealth Management LLC1000 (0.00%)0.00%$0 MOct 14, 2026
50Marshall & Sterling Wealth Advisors Inc.950 (0.00%)0.00%$0 MOct 28, 2026
51Jones Financial Companies Lllp60-6 (-9.09%)0.00%$0 MNov 13, 2026
52Robinhood Markets, Inc.26—0.00%$0 MNov 18, 2026
53NFSG Corp200 (0.00%)0.00%$0 MOct 15, 2026
54Ameritas Advisory Services, LLC150 (0.00%)0.00%$0 MNov 12, 2026
55BNP Paribas Financial Markets70 (0.00%)0.00%$0 MNov 12, 2026
56Danske Bank A/s10 (0.00%)0.00%$0 MNov 9, 2026

Mutual funds holding Veru Inc.#

10 funds hold shares worth $3 M (about 5.3% of the company). Since their previous reports 6 added shares and 1 sold, buying $1 M net.
Mutual funds holding Veru Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.531,940$2 M3.1%<0.01%+40%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.158,165$0 M0.93%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC91,900$0 M0.54%<0.01%+18%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors49,574$0 M0.29%0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC23,036$0 M0.14%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC20,969$0 M0.12%<0.01%+12%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.8,334$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC8,519$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.6,500$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC3,344$0 M0.02%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Veru Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$5 K
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$5 K
open market only
Insiders on file
26
since
$84 K-$335 K$0May 2024: bought $22 K (3 trades), sold $335 K (6 trades)May 24Feb 2025: bought $84 K (2 trades), sold $0 (0 trades)FebAug 2026: bought $5 K (1 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Veru Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed K. Gary BarnetteChief Scientific OfficerBuy+1,800$2.690$5 K2,300Form 4
filed Michael L. RankowitzDirectorBuy+54,721$0.580$32 K250,000Form 4
filed Michael L. RankowitzDirectorBuy+95,279$0.550$52 K195,279Form 4
filed Harry FischChief Corporate Officer, DirectorBuy+4,000$1.250$5 K774,736Form 4
filed K. Gary BarnetteChief Scientific OfficerBuy+5,000$1.340$7 K5,000Form 4
filed Mitchell Shuster SteinerPresident and CEO, DirectorSell-63,379$1.230$78 K6.94 MForm 4
filed Mitchell Shuster SteinerPresident and CEO, DirectorSell-300$1.350$4057.01 MForm 4
filed Mitchell Shuster SteinerPresident and CEO, DirectorSell-6,504$1.390$9 K7.01 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Veru Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.5 M
10.2% of shares · 13.25 days to cover
Dividend per share, Q1 2014
$0.070
0.0% on a year earlier
Buybacks, Q3 2015
$0M
Q4 2015
Shares sold short, last 24 reportsAll stocks →

Bankruptcy filing: (8-K)

Veru Inc. dividends per share by quarter
Dividend, quarterPer share
Q1 2014$0.070
Q4 2013$0.140
Q4 2013$0.070
Q1 2013$0.070
Q4 2012$0.120
Q1 2012$0.060
Q4 2011$0.100
Veru Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2015Q4 2015$0M
Q2 2015Q3 2015$0M
Q3 2014Q4 2014$0.5M
Q2 2014Q3 2014$0.2M
Q3 2013Q4 2013$0M
Q2 2013Q3 2013$0M
Q1 2013Q2 2013$0.2M
Q4 2012Q1 2013$0.2M
Q3 2012Q4 2012$0.2M
Q2 2012Q3 2012$0.1M
Q1 2012Q2 2012$0M
Q4 2011Q1 2012$0M
Q3 2011Q4 2011$0M
Q2 2011Q3 2011$0M
Q1 2011Q2 2012$0M
Q4 2010Q1 2012$0M

Trading halts

  • 2026-06-04 16:14 UTC, code LUDP, resumed 16:24 UTC
  • 2025-08-08 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 660 shares at $2.42
  • : 82 shares at $2.55
  • : 87 shares at $2.51
  • : 506 shares at $2.41
  • : 779 shares at $2.39

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Veru Inc. scorecard#

Passes 2 of the 10 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 9, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.2×Price to book 2.2× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-72.8%Free cash flow is -72.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$23 M-$23 M in fiscal 2025 against -$19 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$23 MNet income -$23 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-89.8%-89.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.43 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Veru Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Veru Inc.: statements by fiscal year
PeriodTrendFY 2025to Sep 30, 2025FY 2024to Sep 30, 2024FY 2023to Sep 30, 2023FY 2022to Sep 30, 2022FY 2021to Sep 30, 2021FY 2020to Sep 30, 2020FY 2019to Sep 30, 2019FY 2018to Sep 30, 2018FY 2017to Sep 30, 2017FY 2016to Sep 30, 2016
Income statement
Revenue—171639614332161422
Cost of revenue—118.78.81312107.1r6.68.8
Gross profit—5.97.6314831228.8r7.013
Research and development1613r51r71r331714113.1r0.1
Selling, general and administrative—314843r21141415r12r8.7
General and administrative2025————————
Operating expenses3637r107r114r5331r2830r1610
Operating income−25−36r−94r−83r13−15−6.4−21−8.53.0
Interest expense and finance costs—0.62.44.44.94.64.73.0——
Other non-operating income (expense)9.10.9r1.1−0.3−8.7−5.3−5.9−2.2−0.1−0.2
Income before tax——−93r−84r4.3−20−12−23−8.62.8
Income tax00r0.50.2−3.1−1.1−0.30.9−2.02.5
Income from continuing operations−16−35————————
Income from discontinued operations−7.0−2.5————————
Net income attributable to shareholders−23−38−93r−84r7.4−19−12−24−6.60.3
Earnings per share, basic-1.55-2.80r-1.10-1.050.10-0.28-0.19-0.44-0.250.01
Earnings per share, diluted——-1.10-1.050.09-0.28-0.19-0.44-0.250.01
Shares, weighted average (basic)1513r85807667——3529
Shares, weighted average (diluted)——8580846763543529
Balance sheet
Cash and cash equivalents16259.6————3.83.32.4
Receivables—4.04.53.68.85.25.04.03.4r11
Inventory—4.16.78.65.66.73.62.32.82.5
Other current assets0.60.8r1.12.00.90.9r1.81.10.8r0.6
Current assets193523r104r1522717111016r
Property, plant and equipment0.40.5r1.71.20.60.30.40.40.60.8
Right-of-use (leased) assets2.73.3r4.34.81.01.4————
Goodwill6.96.96.96.96.96.96.96.96.9—
Other intangible assets—00.04.04.05.8202021—
Total assets306050r135r17852544855r39
Accounts payable3.12.3r13r223.42.83.13.22.70.7
Current liabilities7.81218r39r161514145.53.3
Long-term debt———————1.8——
Lease liabilities (non-current)2.42.9r3.64.10.61.0————
Total liabilities122830r53r262121196.9r4.7
Retained earnings−317−295−257r−164r−82−89−70−58−34−28
Shareholders' equity183220r83r155r3032294834
Total liabilities and equity306050r135r17852544855r39
Shares outstanding1515r9281807065555329
Cash-flow statement
Depreciation and amortization0.20.30.3————0.20.30.4
Share-based compensation8.11418115.12.61.91.60.80.5
Cash from operating activities−30−22−88−48−16−1.9−5.5−121.0−1.7
Capital expenditure−0.0−0.2−0.7−0.7−0.4−0.1−0.1−0.1−0.1−0.0
Acquisitions, net of cash acquired————————−0.0r—
Cash from investing activities250.16.34.315−0.1−0.1−0.1−0.1−0.0
Debt issued—01.4———————
Debt repaid0−0.1−1.3———————
Shares issued————108133.63.0——
Cash from financing activities−4.237111.11109.38.112——
Change in cash−9.115−71−421097.32.50.50.9−1.7
Report10-K10-K10-K10-K/A10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Veru Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.6 M
Mitchell Steiner
Other top executives, average
$855 K
the CEO earned 1.9× this
$100 invested is now
$3
Veru Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mitchell Steiner$1.6 M$1.4 M$855 K$3
2024Mitchell Steiner$2.0 M$1.8 M$926 K$7
2023Mitchell Steiner$4.7 M−$6.0 M$1.6 M$6

Source: SEC proxy statement (Form DEF 14A) · as of Sep 30, 2025

Events at Veru Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Debt called earlyFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 2 · Auditor changed 1 · Debt called early 1 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 4 · Agreement ended 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 5 · Results announced 8

Veru Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Agreement ended8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Directors and officersShareholder vote8-K
Delisting notice8-K
Results announced8-K
Debt called earlyAcquisition or sale completedMaterial agreementAgreement ended8-K
Material agreement8-K
Delisting notice8-K
Agreement ended8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Shareholder vote8-K
Auditor changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 10, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Veru Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2016$23 MPrivate placement after listing$10 to $50 million23equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Veru Inc.#

$0 spent on lobbying the US Congress and federal agencies in 2024, most often on budget/appropriations.

Lobbying, 2024
$0
#1,450 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2024
2026 so far
—
  • Budget/Appropriations4 reports

Lobbying firms hired in 2024

HUSCH BLACKWELL STRATEGIES

Veru Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2024$0—4
2023$170 K—6
2022$410 K—9

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Veru, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Layoffs at Veru Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2009–2009
Latest
—
2009-08-05
Veru Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2009············—
Veru Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Veru Inc. compares in Biotechnology

  • Market cap$41 M · higher than 24% of 726
  • Revenue growth3.6% · higher than 48% of 438
  • Price / book2.3× · lower than 56% of 534
  • FCF yield-72.8% · higher than 15% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Veru Inc.🇺🇸$41 M——+3.6%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 9, 2026
Annual results:
For year ending September-2025
Balance sheet:
As of September-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Veru Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Veru Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Veru Inc.? Suggest a correction